G. Peng

发表

Clobazam‐treated patients with Lennox‐Gastaut syndrome experienced fewer seizure‐related injuries than placebo patients during trial OV‐1012

M. Sperling, J. Isojarvi, Deborah Lee, 2016, Epilepsia.

An exploratory subgroup analysis of race and gender in squamous cancer of the head and neck: inferior outcomes for African American males in the LORHAN database.

C. Obasaju, D. Hayes, A. Hossain, 2014, Oral oncology.

Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Phase I Trial

C. Obasaju, R. Govindan, H. Choy, 2010 .

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

C. Obasaju, G. Scagliotti, R. Herbst, 2010, Clinical lung cancer.

P2-292: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients with advanced (stage IIIB with pleural effusion or IV) non-small-cell lung cancer (NSCLC)

C. Obasaju, J. Arseneau, D. Richards, 2007 .

Deconstructing tolerance with clobazam

R. Sankar, G. Montouris, H. White, 2016, Neurology.

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.

M. Ahn, Yuh-Min Chen, J. Yang, 2012, Lung cancer.

Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.

G. Scagliotti, N. Hanna, C. Langer, 2012, Clinical lung cancer.

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

C. Obasaju, M. Socinski, D. Patt, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.

R. Zinner, S. Saxman, G. Peng, 2010, Clinical lung cancer.

Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update.

C. Obasaju, R. Govindan, H. Choy, 2010 .

Intravenous carbamazepine as short‐term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open‐label trials

J. Halford, V. Biton, I. Bekersky, 2015, Epilepsia.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

C. Obasaju, P. Jänne, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.

C. Obasaju, G. Bepler, M. Schell, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.

C. Obasaju, M. Socinski, G. Scagliotti, 2012, Lung cancer.

Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer

C. Obasaju, R. Govindan, H. Choy, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials

C. Obasaju, G. Scagliotti, R. Herbst, 2008 .

Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)

C. Obasaju, M. Socinski, R. Govindan, 2009, Supportive Care in Cancer.

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

C. Obasaju, G. Scagliotti, R. Herbst, 2010, Clinical lung cancer.

Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology.

R. Zinner, S. Saxman, G. Peng, 2010 .